XJSE
AIP
Market cap731mUSD
Nov 04, Last price
7,480.00ZAR
Name
Adcock Ingram Holdings Ltd
Chart & performance
P/E
13.98
P/S
1.23
EPS
5.35
Div yield, %
3.68%
Shrs. gr., 5y
-2.43%
Rev. gr., 5y
5.85%
Revenues
9.76b
+1.22%
Net income
859m
+5.47%
CFO
432m
-54.18%
Dividend
Sep 17, 2025165 ZAR/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Adcock Ingram Holdings Limited, established in 1890 and headquartered in Midrand, South Africa, operates as a global manufacturer, marketer, and distributor of diverse healthcare products. Its international footprint extends across South Africa, the United States, Canada, the United Kingdom, broader Europe, and other international regions. The company offers a comprehensive product portfolio, including over-the-counter (OTC) remedies, prescription medications, consumer health goods, and specialized medical instrumentation and surgical supplies. Its extensive pharmaceutical range covers numerous therapeutic classes, such as women's health, cannabidiol applications, antiretroviral treatments, dermatology, central nervous system disorders, respiratory conditions, ophthalmology, generic medicines, cardiovascular health, pain relief, gastroenterology, energy and immunity support (including colds and flu remedies, vitamins, minerals, and food/nutrition supplements), personal care, feminine hygiene, digestive well-being, allergy management, baby care, and cough solutions. Beyond its general healthcare offerings, Adcock Ingram also manufactures and supplies essential hospital and critical care products, such as intravenous solutions, renal dialysis systems, and blood collection supplies. The company serves both private and public sectors within the healthcare industry.
Valuation
Title ZAR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||